In the following video, Motley Fool health-care analyst David Williamson discusses a new E.U. approval for Gilead (GILD 0.07%) for its quad pill HIV drug cocktail, which has shares up 2% to near all-time highs. David tells investors why this is just one more piece to the puzzle for Gilead, as it continues to build its empire in the treatment of HIV.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.